Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

NCT04099836 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

Duke University